Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Fortress Biotech, Inc. before investing.

In this article, we go over a few key elements for understanding Fortress Biotech, Inc.’s stock price such as:

• Fortress Biotech, Inc.’s current stock price and volume
• Why Fortress Biotech, Inc.’s stock price changed recently
• Upgrades and downgrades for FBIO from analysts
• FBIO’s stock price momentum as measured by its relative strength

About Fortress Biotech, Inc. (FBIO)

Before we jump into Fortress Biotech, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis. It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine. In addition, the company’s early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator. Further, its preclinical product candidates comprise AAV-ATP7A and AVTS-001 gene therapies; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Want to learn more about Fortress Biotech, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Fortress Biotech, Inc..

Fortress Biotech, Inc.’s Stock Price as of Market Close

As of November 25, 2025, 10:06 AM, CST, Fortress Biotech, Inc.’s stock price was $2.602.

Fortress Biotech, Inc. is up 2.05% from its previous closing price of $2.550.

During the last market session, Fortress Biotech, Inc.’s stock traded between $2.540 and $2.620. Currently, there are approximately 27.24 million shares outstanding for Fortress Biotech, Inc..

Fortress Biotech, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Fortress Biotech, Inc. Stock Price History

Fortress Biotech, Inc.’s (FBIO) price is currently up 1.65% so far this month.

During the month of November, Fortress Biotech, Inc.’s stock price has reached a high of $2.760 and a low of $2.385.

Over the last year, Fortress Biotech, Inc. has hit prices as high as $4.200 and as low as $1.325. Year to date, Fortress Biotech, Inc.’s stock is up 28.51%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Fortress Biotech, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 24, 2025, there was 1 analyst who downgraded Fortress Biotech, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Fortress Biotech, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Fortress Biotech, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Fortress Biotech, Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Fortress Biotech, Inc. (FBIO) by visiting AAII Stock Evaluator.

Relative Price Strength of Fortress Biotech, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 24, 2025, Fortress Biotech, Inc. has a weighted four-quarter relative price strength of 8.91%, which translates to a Momentum Score of 81 and is considered to be Very Strong.

Want to learn more about how Fortress Biotech, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Fortress Biotech, Inc. Stock Price: Bottom Line

As of November 25, 2025, Fortress Biotech, Inc.’s stock price is $2.602, which is up 2.05% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Fortress Biotech, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.